192 related articles for article (PubMed ID: 22607148)
1. Protein kinases as potential targets for novel anti-schistosomal strategies.
Beckmann S; Leutner S; Gouignard N; Dissous C; Grevelding CG
Curr Pharm Des; 2012; 18(24):3579-94. PubMed ID: 22607148
[TBL] [Abstract][Full Text] [Related]
2. Re-positioning protein-kinase inhibitors against schistosomiasis.
Gelmedin V; Dissous C; Grevelding CG
Future Med Chem; 2015; 7(6):737-52. PubMed ID: 25996067
[TBL] [Abstract][Full Text] [Related]
3. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?
Dissous C; Grevelding CG
Trends Parasitol; 2011 Feb; 27(2):59-66. PubMed ID: 20920890
[TBL] [Abstract][Full Text] [Related]
4. Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
Vale N; Gouveia MJ; Rinaldi G; Brindley PJ; Gärtner F; Correia da Costa JM
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264841
[TBL] [Abstract][Full Text] [Related]
5. Targeting kinases in Plasmodium and Schistosoma: Same goals, different challenges.
Doerig C; Grevelding CG
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1637-43. PubMed ID: 25770683
[TBL] [Abstract][Full Text] [Related]
6. Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel.
Kasinathan RS; Sharma LK; Cunningham C; Webb TR; Greenberg RM
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3265. PubMed ID: 25330312
[TBL] [Abstract][Full Text] [Related]
7. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis.
Doenhoff MJ; Cioli D; Utzinger J
Curr Opin Infect Dis; 2008 Dec; 21(6):659-67. PubMed ID: 18978535
[TBL] [Abstract][Full Text] [Related]
8. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Doenhoff MJ; Hagan P; Cioli D; Southgate V; Pica-Mattoccia L; Botros S; Coles G; Tchuem Tchuenté LA; Mbaye A; Engels D
Parasitology; 2009 Nov; 136(13):1825-35. PubMed ID: 19281637
[TBL] [Abstract][Full Text] [Related]
9. The redox biology of schistosome parasites and applications for drug development.
Huang HH; Rigouin C; Williams DL
Curr Pharm Des; 2012; 18(24):3595-611. PubMed ID: 22607149
[TBL] [Abstract][Full Text] [Related]
10. Targeting schistosome histone modifying enzymes for drug development.
Pierce RJ; Dubois-Abdesselem F; Lancelot J; Andrade L; Oliveira G
Curr Pharm Des; 2012; 18(24):3567-78. PubMed ID: 22607147
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Synthesis of Antischistosomal Drugs and Agents.
Liu LX; Li-Li J; Qiong C; Xiao-Lin F
Mini Rev Med Chem; 2017; 17(5):467-484. PubMed ID: 24251801
[TBL] [Abstract][Full Text] [Related]
12. Antischistosomal activity of artemisinin derivatives in vivo and in patients.
Saeed MEM; Krishna S; Greten HJ; Kremsner PG; Efferth T
Pharmacol Res; 2016 Aug; 110():216-226. PubMed ID: 26902577
[TBL] [Abstract][Full Text] [Related]
13. Schistosomiasis--a century searching for chemotherapeutic drugs.
Ribeiro-dos-Santos G; Verjovski-Almeida S; Leite LC
Parasitol Res; 2006 Oct; 99(5):505-21. PubMed ID: 16636847
[TBL] [Abstract][Full Text] [Related]
14. Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.
Chienwichai P; Tipthara P; Tarning J; Limpanont Y; Chusongsang P; Chusongsang Y; Adisakwattana P; Reamtong O
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009706. PubMed ID: 34473691
[TBL] [Abstract][Full Text] [Related]
15. Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection.
Sobhy MMK; Mahmoud SS; El-Sayed SH; Rizk EMA; Raafat A; Negm MSI
Exp Parasitol; 2018 Feb; 185():115-123. PubMed ID: 29331278
[TBL] [Abstract][Full Text] [Related]
16. PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?
Aruleba RT; Adekiya TA; Oyinloye BE; Masamba P; Mbatha LS; Pretorius A; Kappo AP
Infect Disord Drug Targets; 2019; 19(4):337-349. PubMed ID: 30599112
[TBL] [Abstract][Full Text] [Related]
17. Kinases: Molecular Stage Directors for Schistosome Development and Differentiation.
Grevelding CG; Langner S; Dissous C
Trends Parasitol; 2018 Mar; 34(3):246-260. PubMed ID: 29276074
[TBL] [Abstract][Full Text] [Related]
18. Schistosomiasis control: praziquantel forever?
Cioli D; Pica-Mattoccia L; Basso A; Guidi A
Mol Biochem Parasitol; 2014 Jun; 195(1):23-9. PubMed ID: 24955523
[TBL] [Abstract][Full Text] [Related]
19. [Histone deacetylase and histone acetyltransferase inhibitors as antischistosomal agents: a review].
Wang Y; Xu J; Xia C
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2024 Mar; 36(2):207-214. PubMed ID: 38857968
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, anti-schistosomal activity and molecular docking of novel 8-hydroxyquinoline-5-sufonyl 1,4-diazepine derivatives.
Eweas AF; Allam G; Abuelsaad AS; ALGhamdi AH; Maghrabi IA
Bioorg Chem; 2013 Feb; 46():17-25. PubMed ID: 23247256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
